Stock Track | AbCellera Biologics Soars 6.13% After-Hours on Strong Q2 Earnings Beat

Stock Track

Aug 08, 2025

AbCellera Biologics (NASDAQ: ABCL) shares surged 6.13% in after-hours trading on Thursday following the release of its second-quarter earnings report, which significantly exceeded analyst expectations.

The biotechnology company reported a quarterly loss of $0.12 per share, beating the analyst consensus estimate of a $0.15 loss by 21.05%. This represents an improvement from the $0.13 per share loss reported in the same period last year. More impressively, AbCellera's quarterly sales skyrocketed to $17.084 million, surpassing the analyst consensus estimate of $5.824 million by a staggering 193.31%. This marks a substantial 133.29% increase compared to sales of $7.323 million in the same quarter of the previous year.

AbCellera Biologics, known for its AI-powered antibody discovery platform, has been gaining attention in the biotech sector. The company's strong performance this quarter, particularly its ability to more than double its sales year-over-year, suggests growing demand for its innovative technologies. As investors digest this positive earnings surprise, it could potentially lead to revised outlook and increased interest in ABCL stock moving forward.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1177923309"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1177923309\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1177923309?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-08 04:38","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1177923309","market":"sg","top_or_hot":-1,"title":"Stock Track | AbCellera Biologics Soars 6.13% After-Hours on Strong Q2 Earnings Beat","media":"Stock Track","content":"<p>AbCellera Biologics (NASDAQ: ABCL) shares surged 6.13% in after-hours trading on Thursday following the release of its second-quarter earnings report, which significantly exceeded analyst expectations.</p>\n\n<p>The biotechnology company reported a quarterly loss of $0.12 per share, beating the analyst consensus estimate of a $0.15 loss by 21.05%. This represents an improvement from the $0.13 per share loss reported in the same period last year. More impressively, AbCellera's quarterly sales skyrocketed to $17.084 million, surpassing the analyst consensus estimate of $5.824 million by a staggering 193.31%. This marks a substantial 133.29% increase compared to sales of $7.323 million in the same quarter of the previous year.</p>\n\n<p>AbCellera Biologics, known for its AI-powered antibody discovery platform, has been gaining attention in the biotech sector. The company's strong performance this quarter, particularly its ability to more than double its sales year-over-year, suggests growing demand for its innovative technologies. As investors digest this positive earnings surprise, it could potentially lead to revised outlook and increased interest in ABCL stock moving forward.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | AbCellera Biologics Soars 6.13% After-Hours on Strong Q2 Earnings Beat</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | AbCellera Biologics Soars 6.13% After-Hours on Strong Q2 Earnings Beat\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-08-08 04:38</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>AbCellera Biologics (NASDAQ: ABCL) shares surged 6.13% in after-hours trading on Thursday following the release of its second-quarter earnings report, which significantly exceeded analyst expectations.</p>\n\n<p>The biotechnology company reported a quarterly loss of $0.12 per share, beating the analyst consensus estimate of a $0.15 loss by 21.05%. This represents an improvement from the $0.13 per share loss reported in the same period last year. More impressively, AbCellera's quarterly sales skyrocketed to $17.084 million, surpassing the analyst consensus estimate of $5.824 million by a staggering 193.31%. This marks a substantial 133.29% increase compared to sales of $7.323 million in the same quarter of the previous year.</p>\n\n<p>AbCellera Biologics, known for its AI-powered antibody discovery platform, has been gaining attention in the biotech sector. The company's strong performance this quarter, particularly its ability to more than double its sales year-over-year, suggests growing demand for its innovative technologies. As investors digest this positive earnings surprise, it could potentially lead to revised outlook and increased interest in ABCL stock moving forward.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ABCL","symbol_name":"AbCellera Biologics","start_time":0,"source_url":"","article_id":"1177923309","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1177923309","pubTimestamp":1754599126,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"AbCellera Biologics (NASDAQ: ABCL) shares surged 6.13% in after-hours trading on Thursday following the release of its second-quarter earnings report, which significantly exceeded analyst...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ABCL":"AbCellera Biologics"},"translate_title":"个股追踪|AbCellera Biologics盘后飙升6.13%，第二季度盈利强劲","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ABCL":1},"content_text":"AbCellera Biologics (NASDAQ: ABCL) shares surged 6.13% in after-hours trading on Thursday following the release of its second-quarter earnings report, which significantly exceeded analyst expectations.\nThe biotechnology company reported a quarterly loss of $0.12 per share, beating the analyst consensus estimate of a $0.15 loss by 21.05%. This represents an improvement from the $0.13 per share loss reported in the same period last year. More impressively, AbCellera's quarterly sales skyrocketed to $17.084 million, surpassing the analyst consensus estimate of $5.824 million by a staggering 193.31%. This marks a substantial 133.29% increase compared to sales of $7.323 million in the same quarter of the previous year.\nAbCellera Biologics, known for its AI-powered antibody discovery platform, has been gaining attention in the biotech sector. The company's strong performance this quarter, particularly its ability to more than double its sales year-over-year, suggests growing demand for its innovative technologies. As investors digest this positive earnings surprise, it could potentially lead to revised outlook and increased interest in ABCL stock moving forward.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}